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to filter for potential phenotype-relevant target genes. After cloning 
3’-UTR sequences containing predicted miRNA binding sites into 
psiCHECK2 or pmiRGLO vectors reporter gene assays were per-
formed to confirm RNA interference of selected candidate miRNAs 
with their respective target genes.
Results: Of 754 miRNAs, 201 were detected in both tissue types. 
Two miRNAs were differentially expressed in the hippocampus 
relative to the cortex (miR-34c-5p: 7.2-fold higher [q = 0.01], miR-
212-3p: 3.8-fold lower [q = 0.01]). Bioinformatic analysis and fil-
tering for target genes identified 9 genes important for drug efflux, 
neuronal regulation, and signal transmission. Reporter gene experi-
ments confirmed 3 target genes posttranscriptionally regulated by 
miR-34c-5p (GABBR2, GABRA3, GRM7) and 3 target genes regu-
lated by miR-212 (ABCG2, SOX11, ADCY1).
Conclusion: Differential regulation of 2 miRNAs could contribute 
to an altered function of several genes resulting not only in an imbal-
anced neuronal excitability but also in impaired neural differentia-
tion and accelerated drug export. These data suggest multifactorial 
alterations involving miRNA-mediated regulation leading to phar-
macoresistance in epilepsy.
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Introduction: Tolperisone, which is indicated in the treatment of acute 
muscle spasms in back pain and spasticity in neurologic diseases, is a 
centrally acting muscle relaxant. Although the metabolism of tolperisone 
is primarily mediated by CYP2D6, CYP2C19, CYP1A2, and CYP2B6 
are also involved in the biotransformation of tolperisone. Among 3 
drug-metabolizing enzymes, CYP2C19 is a highly polymorphic enzyme. 
The aim of this study was to investigate the effects of CYP2C19 genetic 
polymorphism on the pharmacokinetics of tolperisone.
Patients (or Materials) and Methods: Twenty-six healthy Korean 
subjects were selected and divided into 3 different groups according 
to CYP2C19 genotype, CYP2C19EM (CYP2C19*1/*1, n = 12), 
CYP2C19IM (CYP2C19*1/*2 or *1/*3, n = 7), and CYP2C19PM 
(CYP2C19*2/*2, *2/*3 or *3/*3, n = 7). After overnight fasting, 
each subject received a single 150-mg oral dose of tolperisone. Blood 
samples were collected up to 12 hours after drug intake, and plasma 
concentrations of tolperisone were measured by using LC-MS/MS 
analytical system.
Results: Cmax in CYP2C19PM group was significantly higher 
than that in CYP2C19IM and CYP2C19EM (P = 0.0017 for 
all). AUCinf in CYP2C19PM was also significantly higher than 
that in CYP2C19IM and CYP2C19PM group (P < 0.001 for all). 
Corresponding values for tolperisone in CYP2C19EM and IM groups 
were almost similar (P > 0.05). Apparent oral clearance (CL/F) of 
tolperisone in CYP2C19PM group was 84% lower than that in 
CYP2C19IM group (618 [379] vs 2900 [1343] L/h; P = 0.0010). 
Differences in other parameters of tolperisone between 3 genotype 
groups were not statistically significant.
Conclusion: In Korean healthy subjects, pharmacokinetics of tolp-
erisone are not only influenced by CYP2D6 genotypes but also influ-
enced by CYP2C19 genotypes. Particularly, CYP2C19PM subjects 
had markedly increased plasma concentration of tolperisone com-
pared with CYP2C19EM or CYP2C19IM subjects.
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Introduction: Carbamazepine (CBZ) causes hypersensitivity reac-
tions in a small proportion of patients. There is strong evidence that 
specific human leukocyte antigen (HLA) alleles are associated with 
a higher risk of developing CBZ-induced hypersensitivity. HLA-
A*3101 represents the latest example and is associated with several 
clinical phenotypes of CBZ-induced hypersensitivity in Caucasian 
and Japanese patients. In this study, we aimed to determine whether 
HLA-A*31:01 is functionally implicated in the development of a 
drug-specific immune response in our patient.
Patients (or Materials) and Methods: Peripheral blood mononuclear 
cells (PBMCs) were isolated from a patient with CBZ hypersensitivity 
and the presence of drug-responsive T cells confirmed in vitro using 
the lymphocyte transformation test (LTT). The study was approved 
by the local ethics committee and informed consent was obtained 
from the patient. Drug-specific T cells were enriched in a 4-week 
induction culture and their reactivity tested with enzyme-linked 
immunospot (ELISpot) technique and 51Cr-release assay. T-cell 
clones (TCCs) were generated by serial dilution; characterization 
included CD phenotype, HLA restriction and cytokine profile.
Results: PBMCs responded to CBZ in the LTT with a stimulation 
index (SI) of 15.9. After the 4-week enrichment culture, T-cells were 
shown to secret Interferon-γ (IFN-γ ) and kill 51Cr-loaded target cells 
when exposed to CBZ. Thirty-two CBZ-specific TCCs were gener-
ated; they secreted IFN-γ , interleukin-13 and cytolytic molecules such 
as granzyme B, perforin, and FasLigand. The majority of TCCs were 
CD4+ and T-cell activation was restricted by HLA class II alleles, 
i.e. HLA-DR and -DP. These TCCs proliferated in the presence of 
both CBZ and antigen presenting cells (APCs) expressing HLA-
A*31:01 and HLA-DRB1*04:04, but also in the presence of HLA-
DRB1*04:04+ APCs lacking HLA-A*31:01. HLA-DRB1*04:04 is 
known to be part of a common haplotype with HLA-A*31:01 in 
Caucasians.
Conclusion: We were able to stimulate a secondary immune response 
to CBZ in vitro using lymphocytes from a HLA-A*31:01+ hypersen-
sitive patient. CBZ-specific T cells of CD4+ phenotype were restricted 
by HLA class II alleles, and proliferated in the presence of CBZ and 
HLA-DRB1*04:04+ A*31:01- APCs revealing that a common hap-
lotype may contribute to the multi-clonal response seen in patients 
with CBZ hypersensitivity. Further studies are needed to confirm 
the association.
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Introduction: Two algorithms for acenocoumarol stable dose pre-
diction have been recently published. The first, developed by the 
EU-PACT group includes demographic (age, sex, weight, height, 
amiodarone cotreatment) and genetic variables (genetic variants 
in CYP2C9 and VKORC1 genes). The second one has been devel-
oped by our group (HULP algorithm) in a cohort of 147 patients 
with thromboembolic disease (VTD), including clinic-demographic 
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(age, BMI and presence of amiodarone or metabolic inducers) and 
genetic variables (genetic variants in CYP2C9, VKORC1, CYP4F2 
and APOE genes). Our objective was to test the performance of the 
EU-PACT algorithm in our cohort of patients. Assess the influence of 
factors included in our algorithm but not considered in the EU-PACT 
algorithm, specifically CYP4F2 and APOE variants, and concomitant 
use of metabolic inducers.
Patients (or Materials) and Methods: We evaluated the performance 
of the EU-PACT algorithm in our cohort (HULP) using coefficient 
of determination (R2). To investigate the contribution of vatiants in 
CYP4F2 and APOE, and concomitant metabolic inducers, we com-
pared the real acenocoumarol doses of patients with these variables 
and those doses predicted by both models. A third model was built 
using as independent variables the dose predicted using EUPACT 
algorithm in our cohort, APOE and CYP4F2 variants, and concomi-
tant metabolic inducers. Paired McNemar’s test was used to compare 
both R2.
Results: Variability explained by the EU-PACT’s algorithm when 
applied to our (HULP) cohort was 44.4%. The real mean dose in 
patients with at least 1 of the evaluated variables (CYP4F2, APOE 
variants or metabolic inducers) was 19.3 (8.1) mg/week while the 
dose calculated by the HULP-algorithm was almost the same (19.0 
[5.4] mg/week) and the EU-PACT’s model underestimates almost 3 
mg (16.0 [6.2] mg/week), P < 0.001. The third model, evaluating 
the contribution of CYP4F2 and APOE variants and concomitant 
metabolic inducers, is able to increase the R2 from a 44.4% observed 
with the EU-PACT algorithm to 47.5% (P < 0.05).
Conclusion: EU-PACT shows a reasonable performance in an inde-
pendent cohort with VTD. Inclusion of other known genes involved 
in high dose requirements as CYP4F2 and ApoE and enzyme inducer 
drugs, all included in HULP algorithm, seems to improve prediction 
in acenocoumarol dosing.
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Introduction: Eating behavior has been shown to be affected by the 
brain-derived neurotrophic factor (BDNF). In the present work, we 
have aimed to investigate whether BDNF genetic variability may 
influence physiological and psychopathological features in patients 
with eating disorders (ED) and/or modulate the risk for the disorder.
Patients (or Materials) and Methods: One hundred twenty unrelated 
female patients with anorexia or bulimia nervosa (AN, BN) and 125 
healthy controls were genotyped for BDNF single nucleotide poly-
morphisms (SNPs). Associated psychopathological characteristics 
were assessed by the EDI-2 and SCL-90R inventories.
Results: With regard to physiological parameters, the rs16917237 
TT genotype was associated with increased minimum weight (60.6 
[19.3] vs 50.4 [11.9] kg; P < 0.05) and BMI (23.3 [7.9] vs 19.3 
[4.1]; P < 0.05) in the whole population of patients with ED. The 
risk study showed that only the rs11030119 AA genotype increased 
the risk for AN (OR = 5.23 [1.32–20.98], p = 0.02), although the 
association lost significance after Bonferroni correction. AN patients 
who harbored the -270CC genotype scored higher than CT carriers 
in the Interpersonal Distrust scale of the EDI-2 questionnaire (6.9 
[4.4] vs 2.9 [3.6]; Bonferroni P < 0.05). In the same manner, car-
riers of rs10835210 CC wildtype genotype showed higher scores 
for the Drive for Thinness scale (13.5 [5.0] vs 9.6 [6.0] for patients 
with the variant allele; Bonferroni P < 0.05). Finally, the haplotype 
study showed that 2 combinations (haplotypes *4 and *7) showed 
significantly higher scores in several scales of the EDI-2 and SCL-90R 
inventories than those with the most common haplotype *1. 
Table.  Descriptive and clinical variables of patients with anorexia 
nervosa (AN) or bulimia nervosa (BN) and healthy controls. 
Mean (SD) values are shown.
AN BN Controls P
Age, years 25.4 (7.67) 26.88 (6.88) 22.18 (6.13) NS
Height, m 1.61 (0.07) 1.61 (0.05) 1.62 (0.05) NS
Weight, kg 45.56 (6.44) 60.16 (3.84) 58.1 (9.33) < 0.05a
BMI, kg/m2 17.6 (2.31) 22.88 (5.27) 22.13 (3.45) < 0.05a
Age at onset, 17.16 (5.07) 19.57 (6.7)
Mean duration of 
illness, y
19.63 (7.25) 19.62 (5.9)
Total EDI-2 score 87.46 (42.67) 115.64 (41.88)
GSI (SCL-90R) score 1.54 (0.81) 1.97 (0.89)
PST (SCL-90R) score 60.72 (20.7) 71.02 (17.8)
PSDI (SCL-90R) score 2.17 (0.75) 2.41 (0.57)
Conclusion: Variability in the BDNF gene locus may contribute to 
psychopathological features that are commonly found in ED patients.
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Introduction: Acenocoumarol is an oral anticoagulant of the cou-
marin type. These anticoagulants have a narrow therapeutic index 
and are characterized by a large interpatient variability that can be 
explained by numerous factors, including genetic factors. Dose vari-
ability due to polymorphisms in the VKORC1 and the CYP2C9 genes 
has been well characterized. The aim of our study was to investigate 
the potential association between ABCB1 polymorphisms and the 
time-to-achieve stability during acenocoumarol treatment.
Patients (or Materials) and Methods: We conducted a prospective 
observational study on 115 hospitalized patients, aged 18 years and 
over and starting acenocoumarol. Collected data included sex, age, 
anticoagulant indication, INR measurements, acenocoumarol doses, 
comorbidities, comedications, and genotype (ABCB1 c.3435C> T 
and c.2677G> T/A). Patients were followed from the date of the first 
acenocoumarol administration until time-to-achieve stability or the 
end of the observation period of 35 days. Time-to achieve stability 
was defined as the first 3 consecutive INR measurements within the 
